TetraKit is proud to be part of the AstraTATE project, supported by Innovationsfonden with a total investment of DKK 21.7 million.

The project focuses on developing a novel radionuclide therapy for treating neuroendocrine tumors (NET), using the alpha-emitting isotope astatine-211 (At-211). The aim is to create a more targeted treatment approach that could reduce harm to healthy tissue and improve outcomes for patients.

AstraTATE is a collaboration between Rigshospitalet, Københavns Universitet – University of Copenhagen (CMI), Dept. of Drug Design and Pharmacology (ILF), University of Copenhagen, Minerva Imaging, and TetraKit Technologies — combining research and industry expertise to bring a new generation of cancer treatment closer to patients. ☢️🏥

Read the full press release (in Danish): https://innovationsfonden.dk/da/news-article/ny-radionuklidterapi-kan-revolutionere